Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Patient, Consumer Groups Decry Lack Of User Fee Funding For Post-Market Surveillance

This article was originally published in The Gray Sheet

Executive Summary

Non-industry stakeholders criticized the medical device user fee agreement for not giving FDA enough funding, particularly to enhance post-market surveillance programs, during an FDA public meeting on user fee reauthorization.

You may also be interested in...

Senate Plans FDA User Fee Markup This Week; House Not Far Behind

Updated draft user fee reauthorization bills issued last week reflect works in progress as lawmakers aim to reach consensus on FDA reforms.

Draft User Fee Bills Aim To Streamline And Strengthen Device Regs

Details on draft legislation circulating in the House and Senate.

FDA Sets March 28 Date To Discuss Newly Published Draft User Fee Pact

The agency published its draft commitment letter and draft legislative language for user fee reauthorization March 15. A public meeting is set for the end of the month, and public comments will be accepted through April 16.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts